Cellectis (CLLS) Share-based Compensation Growth (3y) (2018 - 2026)
Powered by 
Analysis
Cellectis (CLLS) Share-based Compensation Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 17.49% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.55% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 30.98% |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | 11.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.64% |
| Mar 31, 2026 | 0.88% |
| Dec 31, 2025 | 79.81% |
| Sep 30, 2025 | -26.02% |
| Jun 30, 2025 | -13.94% |
| Mar 31, 2025 | -25.03% |
| Dec 31, 2024 | -22.96% |
| Sep 30, 2024 | -25.99% |
| Jun 30, 2024 | -40.75% |
| Mar 31, 2024 | 209.22% |
| Dec 31, 2023 | 54.14% |
| Sep 30, 2023 | -40.69% |
| Jun 30, 2023 | -29.28% |
| Mar 31, 2023 | -30.26% |
| Dec 31, 2022 | -62.07% |
| Sep 30, 2022 | -44.97% |
| Jun 30, 2022 | -33.11% |
| Mar 31, 2022 | -23.10% |
| Dec 31, 2021 | -37.85% |
| Sep 30, 2021 | -12.04% |